0001558370-23-015947.txt : 20230922 0001558370-23-015947.hdr.sgml : 20230922 20230922163021 ACCESSION NUMBER: 0001558370-23-015947 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230919 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230922 DATE AS OF CHANGE: 20230922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevation Oncology, Inc. CENTRAL INDEX KEY: 0001783032 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 841771427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40523 FILM NUMBER: 231272098 BUSINESS ADDRESS: STREET 1: 101 FEDERAL STREET STREET 2: SUITE 1900 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7163711125 MAIL ADDRESS: STREET 1: 101 FEDERAL STREET STREET 2: SUITE 1900 CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: 14ner Oncology, Inc. DATE OF NAME CHANGE: 20190719 8-K 1 elev-20230919x8k.htm 8-K
0001783032false00017830322023-09-192023-09-19

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 19, 2023

Elevation Oncology, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware

001-40523

84-1771427

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

​

​

​

101 Federal Street, Suite 1900

Boston, Massachusetts

02110

(Address of Principal Executive Offices)

(Zip Code)

​

(716) 371-1125

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ELEV

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 19, 2023, Elevation Oncology, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until March 18, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to March 18, 2024.

If the Company does not regain compliance by March 18, 2024, the Company may be eligible for an additional 180-calendar day grace period if it applies to transfer the listing of its common stock to The Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on the Nasdaq Global Select Market until the completion of the appeal process.

The Company is considering actions that it may take in response to the Notice in order to regain compliance with the continued listing requirements, but no decision about a response has been made at this time. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.

​

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 21, 2023, Colin Walsh, Ph.D., notified the Company of his resignation from the Board of Directors of the Company (the “Board”), effective immediately. Dr. Walsh’s decision was primarily due to his pursuit of other professional opportunities and was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company thanks Dr. Walsh for his service on the Board and wishes him well in his future pursuits. In connection with Dr. Walsh’s resignation, the Board appointed Steven A. Elms as a member of the Board’s Audit Committee to fill the vacancy left by Dr. Walsh.

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

Elevation Oncology, Inc.

​

Date: September 22, 2023

​

By:

/s/ Tammy Furlong

​

​

Tammy Furlong

​

​

Chief Financial Officer

​

​

 EX-101.SCH 2 elev-20230919.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 elev-20230919_def.xml EX-101.DEF EX-101.LAB 4 elev-20230919_lab.xml EX-101.LAB EX-101.PRE 5 elev-20230919_pre.xml EX-101.PRE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Sep. 19, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Sep. 19, 2023
Entity Registrant Name Elevation Oncology, Inc.
Entity File Number 001-40523
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-1771427
Entity Address, Address Line One 101 Federal Street
Entity Address, Address Line Two Suite 1900
Entity Address, City or Town Boston
Entity Address State Or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 716
Local Phone Number 371-1125
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ELEV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001783032
Amendment Flag false
XML 7 elev-20230919x8k_htm.xml IDEA: XBRL DOCUMENT 0001783032 2023-09-19 2023-09-19 0001783032 false 8-K 2023-09-19 Elevation Oncology, Inc. DE 001-40523 84-1771427 101 Federal Street Suite 1900 Boston MA 02110 716 371-1125 false false false false Common stock, par value $0.0001 per share ELEV NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://elevationoncology.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports elev-20230919.xsd elev-20230919_def.xml elev-20230919_lab.xml elev-20230919_pre.xml elev-20230919x8k.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "elev-20230919x8k.htm": { "nsprefix": "elev", "nsuri": "http://elevationoncology.com/20230919", "dts": { "schema": { "local": [ "elev-20230919.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "definitionLink": { "local": [ "elev-20230919_def.xml" ] }, "labelLink": { "local": [ "elev-20230919_lab.xml" ] }, "presentationLink": { "local": [ "elev-20230919_pre.xml" ] }, "inline": { "local": [ "elev-20230919x8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "report": { "R1": { "role": "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_9_19_2023_To_9_19_2023_7dIFN9rKVkC-b2Q8416Spg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "elev-20230919x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_9_19_2023_To_9_19_2023_7dIFN9rKVkC-b2Q8416Spg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "elev-20230919x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://elevationoncology.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001558370-23-015947-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-015947-xbrl.zip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end